Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSF1 activator
- Development stage
- Preclinical
- Lead developer
- Sisu Pharma
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
Sisu Pharma is developing a small-molecule activator of Heat Shock Factor 1 (HSF1) for the treatment of neurodegenerative conditions. Utilizing the company's proprietary HI-LiTe (HSF1-Interacting-Ligand Technology) platform, this program aims to enhance the cellular heat-shock response and increase the expression of chaperone proteins. By boosting protein-folding capacity, the activator is intended to provide neuroprotective effects against the protein misfolding and aggregation characteristic of neurodegenerative diseases. This approach contrasts with Sisu's oncology pipeline, which focuses on HSF1 degradation to treat solid tumors and hematological malignancies.
- Other names
- HSF1 activatorHSF-1 activatorHSF 1 activatorHI-LiTe HSF1 activator
02
Targets
HSF1 (Heat shock factor protein 1)
Beyond the preview
Go deeper on HSF1 activator.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSF1 activator.